Simulations Plus, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended August 31, 2022. Although the request metadata says “2022 Q4,” this filing reports annual results; it does not provide a clear standalone fourth-quarter financial summary.
Business context
Simulations Plus develops modeling and simulation software for drug discovery and development and provides related scientific consulting. Its two reportable segments are Software and Services. Software generated 61% of FY2022 revenue and Services 39%.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $53.9 million | $46.5 million |
| Gross profit / gross margin | $43.1 million / 80% | $35.9 million / 77% |
| Income from operations | $14.9 million | $11.3 million |
| Net income | $12.5 million | $9.8 million |
| Diluted EPS | $0.60 | $0.47 |
| Operating cash flow | $17.9 million | $19.2 million |
- Revenue increased 16%. Software revenue rose 18% to $32.6 million, led by GastroPlus and MonolixSuite; Services revenue rose 13% to $21.3 million, led by PBPK and QSP/QST.
- Segment gross margins were 91% for Software and 63% for Services, versus 88% and 61%, respectively, in FY2021.
- SG&A increased 21% to $25.0 million, primarily from personnel, insurance, and travel costs. Reported R&D expense declined 21% to $3.2 million, while total R&D spending was $6.4 million, of which $3.2 million was capitalized.
- The income tax provision rose to $2.6 million; the effective tax rate was 17.4%, compared with 11.8% in FY2021.
- Cash and cash equivalents were $51.6 million and short-term investments were $76.7 million at year-end; working capital was $139.1 million. Total liabilities were $10.1 million. The $3.5 million Wells Fargo credit facility expired in April 2022 with no borrowings, and the company chose not to renew it.
- Operating cash flow was $17.9 million. Investing activities provided $4.3 million, mainly reflecting investment purchases and maturities; financing activities used $7.6 million, including $4.8 million of dividends and Lixoft payments. Cash increased $14.6 million during the year.
Material changes and notable items
- Revenue growth accelerated from 12% in FY2021 to 16% in FY2022, with both segments growing. Gross margin expanded three percentage points.
- Net income rose 28%, while operating cash flow declined from $19.2 million. The filing attributes the FY2022 cash-flow reconciliation partly to a $2.6 million use from changes in operating assets and liabilities.
- The company completed the remaining Lixoft holdback and second earnout payments in FY2022: $3.5 million for the earnout and $2.0 million for the holdback, paid in cash and shares. No Lixoft contingent consideration remained at year-end.
- Held-to-maturity short-term investments had $839,000 of gross unrealized losses at year-end, which management attributed primarily to higher interest rates rather than credit deterioration. Their disclosed fair value was $75.8 million versus $76.7 million amortized cost.
- The company declared $0.06 per share quarterly dividends throughout FY2022, totaling $4.8 million. Future dividends remain subject to Board approval.
Outlook, commentary, and risks
- Management described FY2022 as a record year and cited increasing adoption of modeling and simulation, regulatory support for these methods, and demand for consulting expertise. Its stated priorities include product development, expanding sales and scientific teams, marketing, customer collaborations, and strategic acquisitions.
- No quantitative revenue, earnings, or margin guidance is provided in the supplied filing text. Management expects existing capital and operating cash flows to meet foreseeable working-capital and capital-expenditure needs, while noting that acquisitions could require financing.
- Key risks include intense competition and technological change; customer R&D budget reductions, consolidation, cancellations, or delays; recruiting and retaining specialized staff; cybersecurity, data privacy, hosting interruptions, and software defects; fixed-price consulting overruns; international currency and regulatory exposure; and acquisition integration or goodwill impairment.
- Revenue is seasonal, with the first and fourth fiscal quarters generally weaker. International markets contributed 30% of FY2022 revenue. The three largest customers contributed 5%, 3%, and 3% individually.
- The filing reports no pending legal proceedings. Management and the auditor concluded internal control over financial reporting was effective; the auditor issued unqualified opinions on the financial statements and internal controls. Revenue recognition for consulting contracts, particularly estimates of costs to complete, was identified as a critical audit matter.
Important facts for investors to verify
- Whether software and services growth, particularly in GastroPlus, MonolixSuite, and PBPK, continues in subsequent periods.
- Cash conversion and the sustainability of operating cash flow relative to earnings and capitalized software development spending.
- The composition, maturities, credit quality, and interest-rate sensitivity of short-term investments, including unrealized losses.
- Whether rising SG&A and personnel costs remain proportionate to revenue growth, and how much R&D spending is capitalized versus expensed.
- Dividend continuation, acquisition plans and financing needs, customer concentration, and any material changes in contract cost estimates or remaining performance obligations.